Lexicon Pharmaceuticals financials
$1.88−1.05%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21.1M | $5.3M | $14.2M | $28.9M | $1.3M | $26.5M | $1.8M | $1.6M | $1.1M | $672.0K | $148.0K |
| Gross profit | $653.0K | $21.0M | $5.1M | $14.2M | $28.8M | $1.2M | $26.1M | $1.7M | $1.5M | $1.1M | $602.0K | $141.0K |
| Gross margin | 94.4% | 99.5% | 96.2% | 99.9% | 99.9% | 97.6% | 98.7% | 95.9% | 89.9% | 97.3% | 89.6% | 95.3% |
| Operating income | -$26.5M | -$2.6M | -$14.9M | -$12.2M | $3.7M | -$27.5M | -$32.8M | -$63.7M | -$55.4M | -$45.3M | -$59.9M | -$49.6M |
| Net income | -$31.8M | -$1.0M | -$15.5M | -$12.8M | $3.3M | -$25.3M | -$33.8M | -$64.8M | -$53.4M | -$48.4M | -$49.8M | -$50.5M |
| Net margin | −4591.8% | −4.9% | −291.0% | −90.0% | 11.3% | −2004.4% | −127.5% | −3703.5% | −3244.0% | −4282.9% | −7404.2% | −34138.5% |
| Diluted EPS | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.09 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 |
| EBITDA | -$26.4M | -$2.5M | -$14.8M | -$12.0M | $3.9M | -$27.3M | -$32.7M | -$63.6M | -$55.2M | -$45.2M | -$59.9M | -$49.5M |
| Operating cash flow | -$9.2M | -$14.7M | -$17.2M | -$23.8M | $17.0M | -$43.8M | -$21.5M | -$53.6M | -$48.5M | -$55.1M | -$50.5M | -$41.6M |
| Free cash flow | -$9.2M | -$14.7M | -$17.2M | -$23.8M | $17.0M | -$43.8M | -$22.0M | -$53.9M | -$48.8M | -$55.1M | -$50.5M | -$41.7M |
| Diluted shares | 437.7M | 400.2M | 363.2M | 363.4M | 363.6M | 362.1M | 362.4M | 361.5M | 310.8M | 245.4M | 245.8M | 244.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.9M | $38.1M | $34.3M | $49.7M | $21.4M | $62.9M |
| Short-term investments | $149.7M | $132.6M | $61.9M | $66.3M | $117.6M | $132.0M |
| Total debt | $51.4M | $49.7M | $54.0M | $56.5M | $56.1M | $100.7M |
| Total assets | $250.1M | $268.8M | $185.0M | $205.9M | $225.6M | $297.7M |
| Total liabilities | $75.5M | $66.0M | $77.4M | $85.8M | $96.1M | $174.6M |
| Shareholders' equity | $174.5M | $202.9M | $107.5M | $120.2M | $129.4M | $123.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology